Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes ... to launch Mounjaro in new international markets throughout ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Retatrutide is a key part of Eli Lilly's drug pipeline that works ... appears to be even more effective at weight loss. "We believe this potential new medicine can deliver even more weight ...

Eli Lilly LLY-N on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.